NC
PCRX icon

nVerses Capital’s Pacira BioSciences PCRX Stock Holding History

nVerses Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,800
Closed -$51.5K – 1305
2024
Q2 		$51.5K Buy
1,800
+1,600
+800% +$45.5K 0.03% 589
2024
Q1 		$5.84K Buy
+200
New +$6.14K 0.01% 563

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

nVerses Capital's PCRX Position: Q3 2024 in Review

nVerses Capital sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 1,800 shares — an estimated $51.5K sold.

nVerses Capital first reported a position in PCRX in Q1 2024 and held it in 2 quarters. The position peaked at $51.5K in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • nVerses Capital reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 1,800 Pacira BioSciences shares in Q3 2024, an estimated $51.5K.
  • nVerses Capital first reported a position in Pacira BioSciences in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Pacira BioSciences position peaked at $51.5K in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.